Revolutionizing Diabetes Care, One Breakthrough at a Time
Game-changing insulin therapies designed to balance efficacy while proactively managing hypoglycemia.
At Abvance Therapeutics, we’re more than innovators—we’re advocates for every person struggling to balance their diabetes care. Our groundbreaking pipeline of products is designed to do more than control blood sugar. They've been designed to give patients back their freedom, their confidence, and their peace of mind. We hope to do this by reducing or eliminating the constant fear of life-threatening blood sugar excursions.
Innovating New Therapies So People Can Live Their Lives
At Abvance Therapeutics, we believe diabetes care doesn’t have to be a constant source of fear. We exist to transform the lives of people living with diabetes by creating therapies designed to treat diabetes while managing the fear of blood sugar excursions. Our lead program, ABV101, combines insulin and glucagon, and is designed to manage the biggest challenge for diabetes patients: the fear of dangerously low blood sugar.
Our mission is personal.
Diabetes isn’t just a condition—it’s a daily battle. At Abvance, we’ve seen firsthand the strain it puts on families, friends, and even ourselves. We’ve watched loved ones count every carb, fear every dose of insulin, and wake up in the middle of the night with low blood sugar. Our mission is deeply personal: to build a future where people do not have to think about their diabetes every minute of the day.
We’re not just imagining this future—
we’re building it.
With scientifically validated breakthroughs, strategic partnerships, and an unwavering dedication to improving patient outcomes, Abvance is poised to lead the next generation of diabetes innovation.
Our Solution:
Diabetes therapies that balance blood sugar control and risk of hypoglycemia
Many people today have to make difficult compromises between efficacy and fear when managing their diabetes therapies, particularly with insulin. Fear of low blood sugar continues to stop many from reaching their health goals because the response to fear is usually to use less insulin than is needed to keep blood sugars in range.
- Hypoglycemia remains the primary barrier to achieving optimal glycemic control
- Patients struggle to reach A1C targets due to fear of dangerous blood sugar crashes
- Traditional insulin therapy requires constant vigilance and creates ongoing anxiety
- The emotional and physical toll affects both patients and their families
Our Lead Program: ABV101
With ABV101, Abvance is pioneering a new approach leveraging the hypoglycemia safety net provided by glucagon to enable better dosing approaches for insulin and giving patients them back the control they deserve.
- Designed to prevent dangerous blood sugar crashes through smart molecule combination
- May better enable confident glycemic control without compromise
- Envisioned to integrate seamlessly with current treatment protocols
- Endeavoring to transform the patient experience from one of constant vigilance to one of confidence
This isn't designed to be just an incremental improvement – it's a fundamental shift in how we design insulin therapy.
Trusted Partners & Collaborators
A Personal Commitment to Better Diabetes Care
At Abvance, diabetes isn’t just a statistic – it’s part of our story. We’ve stood beside loved ones as they’ve struggled with the highs and lows of insulin therapy. That’s why we’re not just developing treatments – we’re developing hope of a future where fear of hypoglycemia is not constant.
Our commitment goes beyond creating cutting-edge therapies; we are driven by the empathy we feel for every individual managing diabtes. Our leadership team, some of whom have diabetes themselves, is dedicated to transforming care, not just scientifically, but emotionally.
The Abvance concept has its roots in the laboratory of Dr. Alan Cherrington, distinguished diabetes researcher at Vanderbilt University. The Abvance team is a group of diabetes experts committed to bringing this innovation to the people who need it the most by:
All information on this web site relates to investigational new drugs which are limited by Federal law to investigational use only. Abvance does not make any claims to safety or efficacy as to any investigational product. No product discussed on this web site has been approved by any regulatory agency as safe or effective. The purpose of this web site is to provide information to potential industry partners and potential institutional investors.
Website & Branding by Mile End Digital